Operating profit before amortization: alphatau.com (DRTS)

Alpha Tau Medical Ltd. (DRTS) is implementing precision alpha therapy to combat solid tumors. The base EBITDA level reflects the impact of these developments, where the 0.00 level represents the current figure. Development relies on a team of nuclear physicists creating the medicine of the future; however, ultimate success depends on FDA approval and the availability of funds to scale the technology.

To minimize risks amid uncertainty, it is critical for investors to track absolute operating profit, which measures net cash flow from core operations before depreciation and taxes. By analyzing EBITDA fluctuations, one can assess the effectiveness of Alpha Tau Medical Ltd. (DRTS) patent monetization and the ability of its recurring radiation source deliveries to ensure sustainable capital growth.